FDA Diagnostic Office Bests ODE In Decision Times, And Communication
This article was originally published in The Pink Sheet Daily
Executive Summary
510(k)-route diagnostic, imaging and radiation therapy systems may, on average, be in a better position to reach the market a bit sooner than other device types, according to an independent analysis by Booz Allen Hamilton. The reason, says the consulting firm: early and frequent communications by FDA’s diagnostics office.
You may also be interested in...
Big Uptick In Withdrawn 510(k)s Highlighted In Booz Allen Assessment
The consulting group issued its final assessment of FDA’s device review program following a year-long examination; it includes 11 recommendations for improvements. Among the new directives that were not included in Booz Allen’s interim report in December: FDA should perform a large study of withdrawn device submissions to figure out how to limit the growing practice.
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?